Printed in U.S.A. Copyright © 1997 by The Endocrine Society The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1–34) on Bone Histomorphometry and Serum Chemistry in Rats*

PTH treatment can result in dramatic increases in cancellous bone volume in normal and osteopenic rats. However, this potentially beneficial response is only observed after pulsatile treatment; continuous infusion of PTH leads to hypercalcemia and bone abnormalities. The purpose of these studies was to determine the optimal duration of the PTH pulses. A preliminary study revealed that human PTH-(1-34) (hPTH) is cleared from circulation within 6 h after sc administration of an anabolic dose of the hormone (80 microg/kg). To establish the effects of gradually extending the duration of exposure to hPTH without increasing the daily dose, we programmed implanted Alzet osmotic pumps to deliver the 80 microg/kg x day dose of the hormone during pulses of 1, 2, and 6 h/day, or 40 microg/kg x day continuously. Discontinuous infusion was accomplished by alternate spacing of external tubing with hPTH solution and sesame oil. After 6 days of treatment, we evaluated serum chemistry and bone histomorphometry. As negative and positive controls, groups of rats received pumps that delivered vehicle only and 80 microg/kg x day hPTH by daily sc injection, respectively. Dynamic and static bone histomorphometry revealed that the daily sc injection and 1 h/day infusion dramatically increased osteoblast number and bone formation in the proximal tibial metaphysis, whereas longer infusion resulted in systemic side-effects, including up to a 10% loss in body weight, hypercalcemia, and histological changes in the proximal tibia resembling abnormalities observed in patients with chronic primary hyperparathyroidism, including peritrabecular marrow fibrosis and focal bone resorption. Infusion for as little as 2 h/day resulted in minor weight loss and changes in bone histology that were intermediate between sc and continuous administration. The results demonstrate that the therapeutic interval for hPTH exposure is brief, but that programmed administration of implanted hormone is a feasible alternative to daily injection as a route for administration of the hormone.

[1]  R. Turner,et al.  Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. , 1995, Endocrinology.

[2]  R. Turner,et al.  Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. , 1995, Endocrinology.

[3]  J. Caulfield,et al.  Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34). , 1995, Endocrinology.

[4]  W. Jee,et al.  Human parathyroid hormone‐(1–38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  R. Lindsay,et al.  Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.

[6]  J. Riond.  Modulation of the anabolic effect of synthetic human parathyroid hormone fragment-(I-34) in the bone of growing rats by variations in the dosage regimen. , 1993, Clinical science.

[7]  T. Wronski,et al.  Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. , 1993, Endocrinology.

[8]  B. Hollis,et al.  Modulation of ovariectomy-related bone loss by parathyroid hormone in rats , 1990, Mechanisms of Ageing and Development.

[9]  J. Hock,et al.  Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. , 1990, Endocrinology.

[10]  D. Kalu,et al.  Human parathyroid hormone‐(1‐34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  N. Breslau.  Southwestern Internal Medicine Conference: Normal and Abnormal Regulation of 1,25-(OH)2D Synthesis , 1988 .

[12]  J. Hock,et al.  Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. , 1988, Endocrinology.

[13]  W. Koo,et al.  Sequential bone mineral content in small preterm infants with and without fractures and rickets , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  M. Hori,et al.  Effect of human parathyroid hormone (PTH(1-34)) on experimental osteopenia of rats induced by ovariectomy. , 1988, Bone and mineral.

[15]  E. Brown,et al.  Primary hyperparathyroidism with low serum 1,25-dihydroxyvitamin D levels. , 1986, The Journal of clinical endocrinology and metabolism.

[16]  J. Reeve,et al.  Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. , 1985, Clinical science.

[17]  R. Turner.  Mammalian 25-Hydroxyvitamin D-1α-Hydroxylase: Measurement and Regulation , 1984 .

[18]  J M Hock,et al.  Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. , 1984, Metabolic bone disease & related research.

[19]  M. Kleerekoper,et al.  Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. , 1983, The Journal of clinical investigation.

[20]  J. Heersche,et al.  Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. , 1982, Endocrinology.